欧美成一级-欧美成在人线a免费-欧美传媒影-欧美大逼逼-欧美大成色www永久网站婷-欧美大胆a级视频

Cell Therapy
Universal Cell Platform
Quikin CAR-T Platform
Enhanced T Cell Platforms

Universal Cell Platform


Universal Cell Platform (TyUCell?) refers to the use of gene editing technology to transform allogeneic immune cells to eliminate immune rejection. On the basis of ensuring the safety and effectiveness of cell products, it realizes the generalization of immune cell therapy products. Tyucell cell products have the advantages of low cost, wide application range, short production cycle, stable preparation process and good therapeutic effect. The platform can be used for clinical treatment after a large number of expansion of cells from healthy donors. At the same time, it can realize the large-scale and batch production of cell products, significantly reduce the production cost, shorten the waiting time of patients, and provide modern cell therapy products that meet the urgent needs of clinic.


The development of the era of gene therapy

In 2023, the world's first all human targeted BCMA CAR-T therapy "FUCASO" (Equecabtagene Autoleucel) was approved for sale in China for the treatment of recurrent or refractory multiple myeloma (R/R MM)
In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of r/r MM in China, was approved by the FDA for marketing
In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry
In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia
In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA
In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)
In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL)
In 2016, the first generation of single-base editors were developed
In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced
In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)
In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced
In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)
In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced
In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)
Back to top
主站蜘蛛池模板： 成人a毛片免费全部播放 | 日韩欧美亚洲一区二区三区影院 | 亚洲国产另类av | 专区日韩精品一区 | 午夜欧美性视频在线播放 | 男女啪啪抽搐一进一出小说 | 亚洲成a人片在线观看天堂无码 | 国自产拍偷拍福利精品啪啪 | 亚洲日韩一 | 99热这里只有免费国产精品 | 精品国产免费第一区二区 | 免费无码婬片a片aa片 | 熟妇人妻 | 色哟哟av无码一区二区三区 | 99久久人妻无码精品系列蜜桃 | 久久视频这里只有精品 | 在线观看国产高清的网站 | 久草这里 | 最新精品91探花免费播放 | 专注动漫的门户网站 | 日韩国产欧美精品综合二区 | 久久国产婷婷亚洲国产香蕉 | 免费一区二区三区久久 | 国产精品日韩欧美久久综合 | 国内久久婷婷五月综合欲色啪 | 黑人在线观看国产 | 久久vs国产综合色大全 | 91福利视频导航 | 日韩av在线五月天 | 高清无码电影免费专区 | 成人国产亚洲日本在线 | 久久毛片免费精品无码视频 | 国产亚洲色婷婷 | 国产午夜精品理伦片 | 国产国产人在线成免费视频 | 日韩一区欧美亚洲 | 国产一级黄片 | 国产网红主播无码精品久久 | 国产精品玖玖资 | 亚洲精品午夜国产va久久成人 | 国产女同互慰高潮流水视频 |